Skip to main content
Clinical Trials/NCT02956031
NCT02956031RecruitingNot Applicable

Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women

University of Pretoria1 site in 1 country1,500 target enrollmentStarted: December 1, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1,500
Locations
1
Primary Endpoint
Number of women with histologically proven cervical intraepithelial neoplasia grade 2+ (CIN2+) detected using HPV DNA analysis with partial genotyping as primary screen test followed by cervical cytology and immunocytochemistry as triage tests

Study Overview

Brief Summary

Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.

South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.

The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
25 Years to 75 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Informed consent accepted and signed
  • Health seeking behaviour or request for a cervical cancer screening test
  • Willing and able to receive test result by automated text message or clinic visit

Exclusion Criteria

  • Current pregnancy
  • Hysterectomy
  • Current or previous treatment for gynaecological cancer
  • Hesitant or unable to undergo screening and treatment if indicated

Outcomes

Primary Outcomes

Number of women with histologically proven cervical intraepithelial neoplasia grade 2+ (CIN2+) detected using HPV DNA analysis with partial genotyping as primary screen test followed by cervical cytology and immunocytochemistry as triage tests

Time Frame: Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing

Secondary Outcomes

  • Number of women with CIN2+ detected using HPV DNA analysis with partial genotyping that is associated with HPV types 16, 18, 16 and/or 18, only other high risk types(Detected on histology biopsy at colposcopy after initial HPV screening with simultaneous cytology and immunocytochemistry testing)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Professor Greta Dreyer

Professor

University of Pretoria

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge TrialHIV InfectionHuman Papillomavirus-Related Cervical CarcinomaScreening Strategy
NCT06708351Emory University2,280
Completed
Not Applicable
Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA TestCervical Cancer
NCT06518070Universitas Padjadjaran44
Completed
Not Applicable
Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening UptakeCervical Intraepithelial Neoplasia
NCT02095561Instituto Nacional del Cáncer, Argentina6,013
Active, not recruiting
Not Applicable
Primary Cervical Cancer Screening by Self-sampling HPV TestNegative For Intraepithelial Lesion Or MalignancyAtypical Squamous Cells of Undetermined SignificanceAtypical Squamous Cells, Cannot Rule Out High-grade Squamous Intraepithelial LesionLow-Grade Squamous Intraepithelial LesionsCervical CancerHigh-Grade Squamous Intraepithelial LesionsCervical Intraepithelial Neoplasia Grade ICervical Intraepithelial Neoplasia Grade IICervical Intraepithelial Neoplasia, Grade IIIAtypical Glandular CellsAtypical Glandular Cells Not Otherwise SpecifiedAtypical Glandular Cells, Favor NeoplasticAdenocarcinoma in SituCervical AdenocarcinomaHuman Papillomavirus InfectionCervical Squamous Intraepithelial LesionCervical Squamous Cell Carcinoma
NCT05613283Peking University People's Hospital17,875
Completed
Not Applicable
Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2Precancerous ConditionsNeoplasms
NCT01837693Azienda USL Reggio Emilia - IRCCS41,127